NovaBay Pharmaceuticals Names Finance Executive Jeff Zheng to its Board of Directors
September 16 2019 - 06:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
biopharmaceutical company focusing on commercializing Avenova® for
the domestic eye care market, announces that Yenyou (Jeff) Zheng,
Ph.D. has joined the Company’s board as an independent director.
Dr. Zheng will chair the nominating and corporate governance
committee, and will serve on the audit and compensation committees.
He replaces Todd Zavodnick, who has resigned from the NovaBay
board.
“Jeff brings us extensive corporate governance and financial
experience that includes a track record of providing innovative
corporate financing solutions from his many years in an advisory
capacity to microcap companies. We expect to call upon this broad
expertise as we continue to focus on cost-effectively growing
Avenova sales,” said Paul E. Freiman, NovaBay’s Chairman. “We are
grateful for Todd’s contributions to the NovaBay board over the
past two years.”
“This is an exciting time at NovaBay following the successful
completion of financings in June and August. We are now putting
that money to good use by developing new online marketing
initiatives to promote Avenova Direct,” said Justin Hall, NovaBay
president and CEO. “We launched our direct-to-consumer sales
channel in June and see this as our most promising growth
opportunity. We are delighted to welcome Dr. Zheng to our board and
look forward to his guidance.”
Dr. Zheng previously was a financial advisor for various
Canadian public companies including P&P Ventures Inc. (TSX-V:
PPV.H), where he served as President and a director; Damon Capital
Corp (TSX-V: DAM.H), where he was Chief Financial Officer and a
director; and Cantronic Systems Inc. (TSX-V: CTS), where he served
as a director and chair of the audit committee. Dr. Zheng received
a Ph.D. in physics from Flinders University of South Australia.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding our business strategies and future
focus, the composition of our Board of Directors, and generally the
Company’s expected future financial results. These statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results or achievements to be materially
different and adverse from those expressed in or implied by the
forward-looking statements. Factors that might cause or contribute
to such differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, improving sales rep productivity and product
distribution, obtaining adequate insurance reimbursement, and any
potential regulatory problems. Other risks relating to NovaBay’s
business, including risks that could cause results to differ
materially from those projected in the forward-looking statements
in this press release, are detailed in NovaBay’s latest Form 10-Q/K
filings with the Securities and Exchange Commission, especially
under the heading “Risk Factors.” The forward-looking statements in
this release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay informed on
NovaBay’s progress Like us on Facebook Follow
us on Twitter Connect with NovaBay on LinkedIn Visit
NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190916005187/en/
NovaBay Contact Justin Hall
President and Chief Executive Officer 510-899-8800
jhall@novabay.com
Investor
Contact LHA Investor Relations Jody Cain 310-691-7100
jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Feb 2024 to Mar 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2023 to Mar 2024